Skip to main content

Table 2 Anthropological and clinical characteristics of 12 outpatients with COPD, treated with ESAs and intravenous iron for anemia

From: Anemia and iron deficiency in COPD patients: prevalence and the effects of correction of the anemia with erythropoiesis stimulating agents and intravenous iron

Characteristics Number (%)
Age (years) 74.0 [66.5–79.5]
Male 6 (50%)
FEV1 (% predicted) 46.5% [40–55]
FEV1/FVC (% predicted) 65.5 [49–68]
Basal Oxygan saturation (%) 94.5 [92–96]
CHF 9 (75%)
Diabetes Mellitus 6 (50%)
Hypertension 11 (92%)
CKD 12 (100%)
Dyslipidemia 8 (67%)
Obesity 3 (25%)
Smoking 8 (67%)
Inhaled Bronchodilators 12 (100%)
ACE-I 7 (59%)
ARBs 3 (25%)
Beta-blockers 10 (84%)
Statins 8 (67%)
  1. Abbreviations: ACE-I, angiotensin converting enzyme inhibitors; ARBs, angiotensin receptor ii blockers; CHF, congestive heart failure, CKD, chronic kidney disease; ESAs, erythropoiesis stimulating agents; FEV1, one second Forced Expiratory Volume; FVC, Forced Vital Capacity.